Industry Symposium

World CongressTissue Engineering and Regenerative

Medicine International SocietyVienna, Austria

September 5-8, 2012

Organized byTERMIS-AM and TERMIS-EUIndustry Committees

TERMIS-AM Industry Committee

• Established 2009• Mission

– Support commercialization in Tissue Engineering/Regenerative Medicine (TE/RM)

• Goals– Define and address obstacles/hurdles to product

commercialization– Promote collaborations to build a viable TE/RM industry

• Members– Kiki B. Hellman, PhD; The Hellman Group. LLC; Chair– Timothy A. Bertram, DMV, PhD; Tengion– Peter C. Johnson, MD; Avery Dennison– Mark Van Dyke, PhD; Wake Forest University Health Sciences– Bill Tawil, PhD; Baxter Biosurgery

2

TERMIS-EU Industry Committee• Established 2011• Mission

– Motivate translation of academic research into commercial products, in Tissue Engineering/Regenerative Medicine (TE/RM)

– Connect the scientific & clinical communities with TE/RM industries

• Goals– Give answers to critical questions, paving the road of TE/RM

commercial translation, by key stakeholders, from past experiences – Promote academia–industry meetings & partnerships for more

effective commercial translation in TE/RM

• Members– Yves Bayon, PhD; Covidien – Sofradim Production; Chair– Simon Ellison, MBA; NHS Blood & Transplant– John Barry, PhD; Baxter Innovations– Paul Stroemer, PhD, Reneuron– Chris Mason, PhD; University College of London– Alain Vertes, PhD; London Business School Sloan Fellow 3

4

Partnership, the key for successful translation of Regenerative Products

World CongressTERMIS

Organized byTERMIS-AM and TERMIS-EUIndustry Committees

Industry Symposium

Industry SymposiumSESSION 1:

“Commercialization of Regenerative Products: The Academe/Industry Partnership”

World CongressTissue Engineering and Regenerative

Medicine International SocietyVienna, Austria

September 5-8, 2012

Organized byTERMIS-AM and TERMIS-EUIndustry Committees

Commercialization of Regenerative Products: The Academe/Industry Partnership

Organizers:

TERMIS-AM & TERMIS-EU Industry Committees

Main Goals:

• to learn from past academia-industry collaborative experiences in TE/RM commercial development

• to enable academia and industry to understand how best to work together and identify individual collaborations that can rapidly move forward.

6

Commercialization of Regenerative Products: The Academe/Industry Partnership

7

9:05 – 9:20Vienna/Austria - From a Strong Biomedical Tradition to a Future of Innovation and Patient CareEhrlich H, Baxter Bioscience, Austria

9:20 – 9:40Commercialization of regenerative medicine products: the academia-industry partnershipVertès A, London Business School, Sloan Fellowship, UK

9:40 – 10:00Commercializing regenerative medicine therapeutics and sustaining a successful businessArshad A, Scientia Advisors, USA

10:00 – 10:15Translating academic concepts to commercial medical products: A complex academic, industrial partnershipCoury A, Consultant, USA

10:15 – 10:30 Successful translation of academic research using combinations of mesenchymal stromal cells with pharmaceutical agents for clinical applications in regenerative medicine Ghosh P, Mesoblast Ltd, Australia